Alexandria Real Estate Equities, Incの最新の1株当たり利益は$2.1で、$0.13の予想を打ちつける。
Alexandria Real Estate Equities, Inc AREの前四半期の収益はどうでしたか?
Alexandria Real Estate Equities, Incの前四半期の収益は$2.1です。
Alexandria Real Estate Equities, Incの収益見積もりはいくらですか?
13人のウォール街のアナリストによると、Alexandria Real Estate Equities, Incの収益見積もりは$691.53Mから$615.44Mの範囲です。
Alexandria Real Estate Equities, Incの収益品質スコアはどれくらいですか?
Alexandria Real Estate Equities, Incの収益品質スコアはB/35.6268です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Alexandria Real Estate Equities, Incはいつ収益を報告しますか?
Alexandria Real Estate Equities, Incの次の収益報告は2026-07-26に予定されています
Alexandria Real Estate Equities, Incの予想収益はいくらですか?
ウォール街のアナリストによると、Alexandria Real Estate Equities, Incの予想収益は$690.66Mです。
Alexandria Real Estate Equities, Incは収益予想を上回りましたか?
Alexandria Real Estate Equities, Incの最近の収益は$653.01Mで、予想を打ち勝たない。
主要データ
前終値
$50.79
始値
$50.82
当日レンジ
$50.67 - $52.02
52週レンジ
$39.41 - $88.24
取引高
788.0K
平均取引高
2.3M
配当利回り
8.78%
1株当たり利益(TTM)
-6.22
時価総額
$8.9B
AREとは何ですか?
Alexandria Real Estate Equities, Inc. engages in the provision of space for lease. The company is headquartered in Pasadena, California and currently employs 514 full-time employees. The firm is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. The company has a Labspace asset base predominantly concentrated in markets with barriers to entry.